Jefferies resumed coverage on GeneDx with a new price target
$WGS
Retail: Computer Software & Peripheral Equipment
Technology
Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2026 | $155.00 | Equal Weight → Overweight | Wells Fargo |
| 10/20/2025 | $155.00 | Buy | Canaccord Genuity |
| 7/9/2025 | $110.00 | Overweight | Piper Sandler |
| 5/15/2025 | $88.00 | Buy | Guggenheim |
| 5/9/2025 | $80.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $34.00 | Equal Weight | Wells Fargo |
| 7/10/2024 | $43.00 | Buy | Craig Hallum |
| 6/3/2024 | $21.00 | Hold | Jefferies |
GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx's (NASDAQ:WGS) mission is t
New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and in
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag
Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00
Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00
Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
S-8 - GeneDx Holdings Corp. (0001818331) (Filer)
10-K - GeneDx Holdings Corp. (0001818331) (Filer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx's (NASDAQ:WGS) mission is t
Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in r
Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli
Renowned physician–scientist and healthcare innovator to lead GeneDx's vision for a new era of lifelong health informed by genomics GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx's vision to unlock the power of genomics to help every person live their healthiest life. As Chief Precision Medicine Officer, Dr. Lee will lead GeneDx's work to empower customizable precision medicine as the standard of care, leveraging the power of genomics to predict, prevent, and optimize health outcomes throughout a person's lifetime. Precision medicine c
Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)